Abstract
The cannabinoid tetrahydrocannabidivarin (THCV) acts as a neutral antagonist of the CB1 cannabinoid receptor, and may be used for the treatment of obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimers disease, bone disorders, obesity associated with type II (non-insulin dependent) diabetes) or in the treatment of drug, alcohol or nicotine abuse or dependency. THCV may also be used as an appetite suppressant for cosmetic weight loss. THCV may be prepared as a crude extract from a cannabis plant, a purified product or a synthetic molecule. Other neutral antagonists of the CB1 receptor may also be used for the treatment of CB1 related conditions.
| Original language | English |
|---|---|
| Patent number | BRPI0518011 |
| IPC | A61K31/00; A61K31/33; A61K31/454; |
| Publication status | Published - 21 Oct 2008 |
